Veeva Systems Inc. · NYSE:VEEV

Veeva Systems — Investor Day (September 2015)

126 slides from Veeva Systems's investor day presentation, Sep 30, 2015

1. Slide 1: Analyst & Investor Day

   Analyst & Investor Day September 30, 2015 ®2015 Veeva Systems veeva.com |

2. Slide 2: Agenda

   Agenda Cloud Innovation Peter Gassner, Founder & CEO Veeva 2020 Tim Cabral, CFO Industry Dynamics Matt Wallach, Co-founder & President Break Commercial Cloud Matt Wallach, Co-founder & President Vault R&D Avril England, GM, Veeva Vault Customer Chat Ed Gemo, VP & CIO, Halozyme Q&A ®2015 Veeva System

3. Slide 3: Safe Harbor

   Safe Harbor Forward-looking Statements This presentation contains forward-looking statements, including statements regarding Veeva's future financial outlook and financial performance, market growth, the release dates for and benefits from the use of Veeva's solutions, our partnership plans, our str

4. Slide 4: Cloud Innovation

   Cloud Innovation Peter Gassner, Co-founder & CEO ®2015 Veeva Systems veeva.com |

5. Slide 5: The Leading Provider of Cloud Solutions to the Global Life Sciences Industry

   The Leading Provider of Cloud Solutions to the Global Life Sciences Industry Founded in 2007 $313M FY15 Revenue 1400+ Employees HQ in Pleasanton, CA ®2015 ®2015 Veeva Systems – Company Confidential Veeva Systems veeva.com | 5

6. Slide 6: Vision and Values

   Vision Become the Leading Cloud Solutions Provider to the Global Life Sciences Industry Values Customer Success Employee Success Speed ®2015 ®2015 Veeva Systems – Company Confidential Veeva Systems veeva.com | 6

7. Slide 7: Key Highlights

   Key Highlights  Well positioned for long-term growth  Sustainable profitably and cash flow  Large Commercial Cloud opportunity  Vault established as second growth engine  Innovation DNA ®2015 Veeva Systems veeva.com | 7

8. Slide 8: Two Years Since Veeva's IPO

   Two Years Since Veeva’s IPO What’s changed…  Operating at scale  $98M revenue in Q2  More than doubled headcount to 1,400  Success across multiple product lines  Non-CRM revenue from ~5% to 23% in Q2  More products  Significant innovations in each product line  Five new products announced 

9. Slide 9: Two years since Veeva's IPO

   Two years since Veeva’s IPO What hasn’t…  Industry Cloud model  High growth  Non-GAAP operating margins in the 20’s  Consistent execution  Exceeded topline guidance every quarter as a public company  Customer success  World-class revenue retention rates consistently well above 100%  Rapid in

10. Slide 10: Industry Cloud Model

    Industry Cloud Model Software Data Services ®2015 Veeva Systems veeva.com | 10

11. Slide 11: The real advantage of an industry-specific solution

    “The real advantage of an industry- specific solution is that it eliminates, or significantly reduces, the need to customize. We can deploy and achieve business results faster. It is about speed to value.” CIO, Top 30 Pharma ®2015 Veeva Systems veeva.com |

12. Slide 12: Largest Segment of the Software Market

    Largest Segment of the Software Market Total Worldwide Software Market Share, 2014 Vertical Specific Software 9% Operating Systems 3% 4% Database Management Systems Other Application Software 4% 27% ERP 4% $115B App Infrastructure / Middleware CRM 4% IT Operations 5% Security 8% Office Suites 5% Sto

13. Slide 13: ...and with the Most Growth

    Change in spending from 2013 ($B) Thousands -2 -1 0 1 2 3 4 5 6 7 8 Vertical Specific ®2015 Veeva Systems Other applications CRM Middleware DMS ERP IT Ops Security Source: Gartner, Market Share: All Software Markets Worldwide 2014, March 2015 Supply Chain Mgmt Storage Mgmt BI & Analytics Social …and

14. Slide 14: Innovation DNA

    Innovation DNA  Product Enhancements  New Applications  More Data  New Product Lines  Veeva Labs ®2015 Veeva Systems veeva.com | 14

15. Slide 15: Veeva Spans an Entire Life Sciences Company

    Veeva Spans an Entire Life Sciences Company Research & Development Medical Commercial Clinical Quality and Medical Field Regulatory Marketing Sales Trials Manufacturing Affairs Medical Approved Events Align CRM CLM Engage CoBrowse Email Management Regulatory Investigator Information eTMF QualityDocs

16. Slide 16: Partner to the Industry

    Partner to the Industry Customer Count by Product Line* 500 Q2’16 450 31 Network 400 22 66 OpenData 350 53 300 7 9 170 Vault 135 250 6 27 200 69 150 31 100 191 198 CRM 11 147 50 116 81 0 FY12 FY13 FY14 FY15 Q2’16 ®2015 Veeva Systems *Not Including Zinc Ahead veeva.com |

17. Slide 17: Product Evolution

    Product Evolution Integrated Industry Cloud Multiple Global Product Lines Single Global Product Line Single Product Line ®2015 Veeva Systems veeva.com | 17

18. Slide 18: Strategic Partner to the Industry

    Strategic Partner to the Industry From Nowhere to 3rd Most Preferred Life Sciences Software Vendor, IDC Health Insights Ranking 2015 2014 2013 2012 1 Oracle Oracle Oracle Oracle 2 SAP SAP SAP Apple 3 Veeva Symantec Symantec SAP 4 Medidata Veeva SAS SAS 5 SAS SAS IBM Microsoft 6 Microsoft IBM Microso

19. Slide 19: Targeting $1B Revenue Run Rate in CY2020

    Targeting $1B Revenue Run Rate in CY2020 Veeva Today CY2020e Total Revenue ~$400M $1B FY16 Guidance Revenue Run Rate Non-CRM Revenue 20%+ ~50% Eight-figure Customers 8 20 Customers 350 500+ ®2015 Veeva Systems veeva.com | 19

20. Slide 20: Veeva in 2020

    Veeva in 2020 Tim Cabral, CFO ®2015 Veeva Systems veeva.com |

21. Slide 21: History of Strong Revenue Growth

    History of Strong Revenue Growth $401M Updated guidance for Zinc acquisition $313M $210M $130M $61M $29M FY'11 FY'12 FY'13 FY'14 FY'15 FY'16 Subscription Services Note: FY’16 revenue is based on the mid-point of most recently provided guidance ®2015 Veeva Systems veeva.com |

22. Slide 22: Targeting $1B Revenue Run Rate in CY2020

    Targeting $1B Revenue Run Rate in CY2020 Veeva Today CY2020e Total Revenue ~$400M $1B FY16 Guidance Revenue Run Rate Non-CRM Revenue 20%+ ~50% Eight-figure Customers 8 20 Customers 350 500+ ®2015 Veeva Systems veeva.com | 22

23. Slide 23: Partner to the Industry

    Partner to the Industry Customer Count by Product Line* 500 Q2’16 450 31 Network 400 22 66 OpenData 350 53 300 7 9 170 Vault 135 250 6 27 200 69 150 31 100 191 198 CRM 11 147 50 116 81 0 FY12 FY13 FY14 FY15 Q2’16 ®2015 Veeva Systems *Not Including Zinc Ahead veeva.com |

24. Slide 24: Product Line Contribution for $1B Target

    Product Line Contribution for $1B Target $1B ~50% ~$400M 75% ~35-40% 20% ~10-15% 2015 2020 (FY16 Guidance) (CY Revenue Run Rate) CRM Vault Network / OpenData / Other ®2015 Veeva Systems veeva.com |

25. Slide 25: Vault Tracking Ahead vs. Early Days of CRM

    Vault Tracking Ahead vs. Early Days of CRM Total revenue through first ~4 years of sales by product line Vault CRM Quarters after product line launch Note: First quarter of sales was Q2’08 for CRM and Q2’12 for Vault ®2015 Veeva Systems veeva.com |

26. Slide 26: Current CRM & Vault Revenue Trends

    Current CRM & Vault Revenue Trends Total revenue by product line CRM Vault Quarters after product line launch ®2015 Veeva Systems veeva.com |

27. Slide 27: 2020 Target Implies Trajectory for Vault Similar to CRM

    2020 Target Implies Trajectory for Vault Similar to CRM Implied trajectory of Vault revenue in $1B target CRM Vault Quarters after product line launch ®2015 Veeva Systems veeva.com |

28. Slide 28: Vault Customers Expand Over Time

    Vault Customers Expand Over Time Annualized Vault subscription revenue by annual cohort Avg. Vaults per customer 1.3 1.2x 3.0x 2.0 9.6x 2.2 First year Q2'16 ®2015 Veeva Systems 2013 2014 2015 veeva.com |

29. Slide 29: Adding Value to Customers

    Adding Value to Customers Seven-figure and eight-figure customer count 20 in 2020 45 42 39 40 8 >7-fig. customers 35 7 34 7 7 >8-fig. customers 6 7 28 25 5 4 35 37 32 33 28 28 23 21 Q3'14 Q4'14 Q1'15 Q2'15 Q3'15 Q4'15 Q1'16 Q2'16 ®2015 Veeva Systems veeva.com |

30. Slide 30: Lots of White Space Remaining

    Lots of White Space Remaining Dollar penetration within large enterprise customers with current products 5% 33% 14% 2% CRM Vault veeva.com | ®2015 Veeva Systems Network/OpenData

31. Slide 31: Customer Count Penetration

    Customer Count Penetration Commercial R&D Only Total Life sciences 500 2,000 2,500 companies Customer count 238* 113 351 today Penetration 48% 6% 14% New customers - 70 51 121 last 4 quarters Projected adds for ~50 ~125 +175 2020 goal Annual target adds 10 25 *Includes net new customers from Zinc ac

32. Slide 32: Well Positioned for $1B in CY2020

    Well Positioned for $1B in CY2020 TODAY CY2020e Total Revenue $1B Revenue Run Rate Non-CRM Revenue ~50% Eight-figure Customers 20 Customers 500+ ®2015 Veeva Systems veeva.com |

33. Slide 33: Long-term Operating Model

    Long-term Operating Model 2015 2020 (FY’16) (FY’21) Improved revenue mix Gross margin 67-68% Greater non-CRM contribution to revenue 72-73% Scaling of R&D sales team & support S&M % of revenue 17-18% Geographic expansion 17-18% New product innovation R&D % of revenue 14-15% Investments for future pr

34. Slide 34: Billings Deep Dive

    Billings Deep Dive ®2015 Veeva Systems veeva.com |

35. Slide 35: New Orders are Billed with Varying Terms

    New Orders are Billed with Varying Terms  Annual  12 months paid up-front  Quarterly  3 months paid up front  Coterminous  1-11 months paid up front, depending on pre-existing renewal date  Followed by a 12-month renewal bill at pre-existing renewal date ®2015 Veeva Systems veeva.com | 35

36. Slide 36: Illustrative Coterminous Order

    Illustrative Coterminous Order Jan Jul Jan Existing business $100 ACV $100 invoice Jan 1 New business $100 ACV $50 invoice Jul 1 Combined business $200 ACV $200 invoice Jan 1 ®2015 Veeva Systems veeva.com | 36

37. Slide 37: Illustrative Impact on Billings

    Illustrative Impact on Billings Example: $100 order is signed on July 1st… Annual Contract Billings in fiscal Notes Value (ACV) year Annual $100 $100 12 months paid up front Two quarterly invoices of Quarterly $100 $50 $25 each One stub invoice of $50 Coterminous¹ $100 $150 followed by an annual bil

38. Slide 38: FY2016 Billings Growth is Impacted by Two Things

    FY2016 Billings Growth is Impacted by Two Things  Unusually high billings in FY2015 relative to 1 new ACV booked  Realignment of two large customer orders 2 ®2015 Veeva Systems veeva.com | 38

39. Slide 39: FY2015 was an Unusual Billings Year

    1 FY2015 was an Unusual Billings Year  Historically, Veeva has billed an average of 70-80 cents for each dollar of ACV booked in a given fiscal year  In FY2015 the average was just over one dollar  As previously discussed, the difference between these two was approximately $30M less ®2015 Veeva S

40. Slide 40: Two Large Customer Orders Recently Realigned Their Renewal Dates

    2 Two Large Customer Orders Recently Realigned Their Renewal Dates  A ~$14M annual renewal was moved from mid- January to early February  In January, we billed that customer for 12 ½ months and will bill them again in February for 12 months as normal  This means that ~$14M of billings came out of

41. Slide 41: Expect Adjusted Billings Growth of ~30% in FY2016

    Expect Adjusted Billings Growth of ~30% in FY2016 (organic only¹) ($M) FY2015 ($M) FY2016 Calculated billings in FY2015 359 Expected actual billings in FY2016 406 % growth 13% Impact of unusually high billings (30) Impact of renewal date realignments 20 Adjusted billings in FY2015 329 Adjusted billi

42. Slide 42: Billings Growth can be Misleading

    Billings Growth can be Misleading Comparative y-o-y growth: annualized subscription revenue vs. subscription billings 76% 68% 62% 63% 59% 49% 42% 38% 39% 31% 20% 10% Q1'15 Q2'15 Q3'15 Q4'15 Q1'16 Q2'16 % annualized subscription revenue growth % subscription billings growth¹ ¹Subscription billings =

43. Slide 43: Investment Highlights

    Investment Highlights  Industry leading growth and profitability  Multiple product lines with several complementary growth vectors  Blue chip global customer base  Massive white space remaining for current products  Sustained strong operating model as we continue to innovate and scale  Well po

44. Slide 44: Life Sciences Industry Cloud Market Opportunity

    Life Sciences Industry Cloud Market Opportunity Matt Wallach, Co-founder and President ®2015 Veeva Systems veeva.com |

45. Slide 45: Life Sciences Industry is Large and Growing

    Life Sciences Industry is Large and Growing Pharma Biotech Medical Products 6% Life Sciences Tools CAGR Sources: MarketLine Industry Profile Global Health Care Equipment & Supplies, June 2013, Reference Code: 0199-2067 was published July 2013 (Table 4). MarketLine Industry Profile Global Pharmaceuti

46. Slide 46: Annual Life Sciences Spending

    Annual Life Sciences Spending $195B $116B Research & Sales & Development Marketing Sources: thepharmaletter, “Worldwide pharma industry marketing investment flat in 2013,” April 2014 Battelle/R&D Magazine, 2014 Global R&D Funding Forecast, December 2013 ®2015 Veeva Systems veeva.com | 46

47. Slide 47: Significant IT Spend and Large Market Opportunity

    Significant IT Spend and Large Market Opportunity $52B Annual Life Sciences IT Spending $5B+ Current Addressable Market $19B $2B Sales Productivity & Compliance Tools (CRM) Infrastructure $1B Master Data Management & Data (Network & OpenData) $33B Software & Services $2B Content Management (Vault) S

48. Slide 48: Annual Sales & Marketing IT Spending

    Annual Sales & Marketing IT Spending Best Practices: 2015 Life Science Sales and Marketing IT Benchmark Guide 5% CAGR $3.3B Sales & Marketing IT Spending Does Not 2014 Include Data Source: IDC, Best Practices: 2015 Life Science Sales and Marketing IT Benchmark Guide, July 2015 ®2015 Veeva Systems ve

49. Slide 49: 2015 Sales and Marketing IT Spending

    2015 Sales and Marketing IT Spending Looking forward over the next 12 months, do you anticipate your organization-wide sales and marketing IT budget will increase, stay the same, or decrease? Decrease 15% 21% Constant Increase 64% # of Companies Source: IDC, Best Practices: 2015 Life Science Sales a

50. Slide 50: Veeva TAM in 2007

    Veeva TAM in 2007 Potential Future Add-ons Aggregate Spend Alignments Analytics/BI Closed Loop Marketing Compliance Management Consent Management eDetailing Events Management Expense Reporting CRM Field Email eLearning Incentive Compensation $2B Predictive Modeling Route Planning Core SFA Potential

51. Slide 51: Veeva TAM in Fall 2013

    Veeva TAM in Fall 2013 Content Management R&D $2B Commercial CRM MDM / Data $2B $1B Current Core SFA Potential add-ons add-ons ®2015 Veeva Systems veeva.com | 8

52. Slide 52: Veeva TAM in September 2015

    Veeva TAM in September 2015 Registrations Tracking & Submissions Archive Content Management R&D $2B Commercial CRM MDM / Data $2B $1B Current Core SFA Potential add-ons add-ons ®2015 Veeva Systems veeva.com | 9

53. Slide 53: Potential Areas for TAM Expansion

    Potential Areas for TAM Expansion New Vault Products Registrations Tracking & Submissions Archive Content Management New Product Lines R&D $2B Commercial CRM MDM / Data New Data $2B $1B Products Current Core SFA Potential add-ons add-ons ®2015 Veeva Systems veeva.com | 10

54. Slide 54: The Life Sciences Industry Cloud

    The Life Sciences Industry Cloud ®2015 Veeva Systems veeva.com |

55. Slide 55: Life Sciences Industry Dynamics

    Life Sciences Industry Dynamics Margin Continued Multichannel Increasing Legacy Pressure Consolidation Sales & Regulation Technology Marketing ®2015 Veeva Systems veeva.com | 55

56. Slide 56: Focused on the Industry's Highest Priorities

    Focused on the Industry’s Highest Priorities Research & Commercial Development Regulatory Compliance ®2015 Veeva Systems veeva.com | 56

57. Slide 57: Veeva Spans an Entire Life Sciences Company

    Veeva Spans an Entire Life Sciences Company Research & Development Medical Commercial Clinical Quality and Medical Field Regulatory Marketing Sales Trials Manufacturing Affairs Medical Approved Events Align CRM CLM Engage CoBrowse Email Management Regulatory Investigator Information eTMF QualityDocs

58. Slide 58: Integrated and Best-of-Breed

    Integrated and Best-of-Breed VEEVA COMMERCIAL CLOUD VEEVA R&D CLOUD Regulatory Clinical Quality SINGLE SOURCE OF TRUTH ®2015 Veeva Systems veeva.com | 58

59. Slide 59: Select Veeva Customers

    Select Veeva Customers 300+ customers with users in over 80 countries Enterprise Emerging Growth ®2015 Veeva Systems veeva.com | 59

60. Slide 60: Continued Cloud Innovation

    Continued Cloud Innovation Major Veeva Product Releases 2007 2015 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Major Product Releases ®2015 Veeva Systems veeva.com | 60

61. Slide 61: Large and Growing Industry Partner Ecosystem

    Large and Growing Industry Partner Ecosystem Software Content & Data Implementation & Support ®2015 Veeva Systems veeva.com | 61

62. Slide 62: Competitive Advantage

    Competitive Advantage Large Installed Deep Industry Expertise Regulatory Base with Strong Industry-Specific Coupled with Compliance in Customer Functionality Cloud Talent the Cloud Success ®2015 Veeva Systems veeva.com | 62

63. Slide 63: Veeva Commercial Cloud

    Veeva Commercial Cloud ®2015 Veeva Systems veeva.com |

64. Slide 64: 2014 New Drug Approvals Hit 18-year High

    2014 New Drug Approvals Hit 18-year High 44 25+ Product approvals Product approvals 2014 2015 Sources: Forbes: 2014 New Drug Approvals Hit 18-Year High. Jan 2, 2015 Forbes: The FDA Is Basically Approving Everything. Here’s the Data to Prove It. Aug 20, 2015 ®2015 Veeva Systems veeva.com | 64

65. Slide 65: Multichannel is Now

    Multichannel is Now 72% 66% $247 MILLION Want More Cost of Non- Prefer Emails Channels compliance ‘What Physicians Want,’ Publicis Touchpoint Solutions, 2012. ‘Email or snail mail from pharma?’ FiercePharma, 2012. ‘Pharmaceutical Industry Criminal and Civil Penalties.’ Public Citizen, 2012. ®2015 Ve

66. Slide 66: Interact at Customer's Convenience

    Interact at Customer’s Convenience Face-to-face Remote Field Online Event Field-guided Field-guided Email Self-guided Management ®2015 Veeva Systems veeva.com | 66

67. Slide 67: Orchestrated Customer Journey

    Orchestrated Customer Journey Sales Marketing Digital ®2015 Veeva Systems veeva.com | 67

68. Slide 68: Today's Life Sciences Siloes

    Today’s Life Sciences Siloes Sales Marketing Digital ®2015 Veeva Systems veeva.com | 68

69. Slide 69: Veeva Commercial Cloud

    Veeva Commercial Cloud Customer Master Events Management Align CLM DATA INTERACTIONS Approved Multichannel Email Customer Data Sales & KOL Data Marketing Engage CoBrowse CONTENT PromoMats MedComms Service Cloud ®2015 Veeva Systems veeva.com | 69

70. Slide 70: Commercial Evolution

    Commercial Evolution Coordinated Multichannel Multichannel Execution Digitally Enabled Rep Field Rep Face-to-face ®2015 Veeva Systems veeva.com | 70

71. Slide 71: Enable Compliance

    Enable Compliance Compliant Compliant Compliant Interactions Content Operations On-label Messaging MLR Approvals Pre-validated Sunshine Expense Auto Update Opt-in & Approvals Capture Auto Withdrawals Samples Tracking Electronic Signatures Consumption Sample Limits Tracking Spend Reporting ®2015 Veev

72. Slide 72: Commercial Cloud Demo

    Commercial Cloud Demo Vault Veeva CRM & Approved Email Veeva Network PromoMats CLM & Events & OpenData ®2015 Veeva Systems veeva.com | 29

73. Slide 73: Veeva Commercial Cloud Benefits

    Veeva Commercial Cloud Benefits Multitenant cloud computing Reduces the integration burden Improves Enables move to multichannel Compliance Improves product launches Speeds acquisition payback ®2015 Veeva Systems veeva.com | 73

74. Slide 74: Commercial Content Management Market

    Commercial Content Management Market Vault PromoMats Vault MedComms ®2015 Veeva Systems veeva.com |

75. Slide 75: Commercial Content Management

    Commercial Content Management Agency Medical, Legal and Distribute to CRM Global Searching Collaboration Regulatory Reviews and other Channels Creation Review & Distribution Storage Approval Correspon- Websites Medical dence Brochures Radio Ads Letters Apps Contracts Labeling Print Ads TV Ads ®2015

76. Slide 76: Challenges with Commercial Content

    Challenges with Commercial Content Ownership & Multichannel Regulatory Tracking & Control Distribution Risk Visibility Internal & agency Inefficient manual Use of outdated Multichannel, collaboration processes materials claims tracking ®2015 Veeva Systems veeva.com | 76

77. Slide 77: Content Drives Competitive Advantage

    Content Drives Competitive Advantage Create Review Approve Distribute Consume Optimize Analyze ®2015 Veeva Systems veeva.com | 77

78. Slide 78: Powerful Combination

    Powerful Combination • Cements leadership in life sciences commercial content management • Improves position to capture more of the Commercial Cloud opportunity • Speeds Veeva’s move to become industry standard for enterprise content management ®2015 Veeva Systems veeva.com | 78

79. Slide 79: Veeva CRM Approved Email

    Veeva CRM Approved Email ®2015 Veeva Systems veeva.com |

80. Slide 80: Veeva Approved Email

    Veeva Approved Email Productive reps, without the risk Extends Value of Personalized Compliant Activity Insights In-person Meeting ®2015 Veeva Systems veeva.com | 80

81. Slide 81: Approved Email Success

    50+ 6 40% Customers Regions Avg Open Rate Approved Email Success Avg Unsubscribe Number Avg Click-through Rate Rate 32% 57% 11% .1% Phone Desktop Tablet 18% ®2015 Veeva Systems – Company Confidential veeva.com | ‹#› ®2015 Veeva Systems veeva.com |

82. Slide 82: Veeva OpenData

    Veeva OpenData ®2015 Veeva Systems veeva.com |

83. Slide 83: Every Healthcare Professional

    Every Healthcare Professional Demographic Identifiers Name Local identifiers Gender HCP – HCO Age RPPS, BIG, INAMI, GMC Status Specialties Primary Practice Address Credentials Additional Addresses Degrees Certifications Physicians Medical School Contact & Preference Pharmacists Graduation Dates Phon

84. Slide 84: HCP in Veeva CRM

    HCP in Veeva CRM ®2015 Veeva Systems veeva.com | 84

85. Slide 85: Every Healthcare Organization

    Every Healthcare Organization Private Practice Hospitals Locations Life Sciences centric data model reflecting every local Healthcare System and organisational structure Pharmacies Health Systems ®2015 Veeva Systems veeva.com | 85

86. Slide 86: HCO in Veeva CRM

    HCO in Veeva CRM ®2015 Veeva Systems veeva.com | 86

87. Slide 87: Data Quality Remains a Challenge

    Data Quality Remains a Challenge Source: Veeva Systems, “European Life Sciences Industry Survey on Customer Data” March 2015. ®2015 Veeva Systems veeva.com | 87

88. Slide 88: Veeva OpenData Global Roadmap

    Veeva OpenData Global Roadmap Budapest Paris Pleasanton Philadelphia Shanghai Sydney OpenData Offices AVAILABLE END of 2015 2016 ®2015 Veeva Systems veeva.com | 88

89. Slide 89: OpenData KOL – Key Opinion Leader Data

    OpenData KOL – Key Opinion Leader Data Roles & Relationship affiliations mapping Content Reach of analytics the KOL Sentiment analytics Channel relevance ®2015 Veeva Systems veeva.com | 46

90. Slide 90: Veeva CRM Events Management

    Veeva CRM Events Management ®2015 Veeva Systems veeva.com |

91. Slide 91: Events Management in Life Sciences

    Events Management in Life Sciences $3.5B 1,000,000 annually events Hard Coordination Marketing Medical Sales Outsourced Partners Source: IMPACT: MPI, Healthcare Meeting Compliance Certificate, June 2015 ®2015 Veeva Systems veeva.com | 91

92. Slide 92: The Need for a Coordinated Approach

    The Need for a Coordinated Approach Sunshine Act KOL engagement focused the value is a high priority x Events are a high Staff and external value element of partners need a multichannel collaborative strategy process Lack of Visibility Hinders Collaboration ®2015 Veeva Systems veeva.com | 92

93. Slide 93: Better Events with Improved Compliance

    Better Events with Improved Compliance Request Closeout Approvals Event Lifecycle Manage Planning ®2015 Veeva Systems veeva.com | 93

94. Slide 94: Commercial Cloud – Growth Opportunities

    Commercial Cloud – Growth Opportunities ®2015 Veeva Systems veeva.com |

95. Slide 95: Commercial Cloud Growth Areas

    Commercial Cloud Growth Areas Winning more SFA seats Sell existing CRM add-ons to Increase market share with existing and new customers Veeva Network 50+% 10% <5% New Comm’l Products Increase market share in Develop new CRM add-ons, new Increase market share with Commercial Content data products, ne

96. Slide 96: Veeva Vault R&D

    Veeva Vault R&D Avril England, GM Vault Steve Harper, Director Vault Product Management ®2015 Veeva Systems veeva.com |

97. Slide 97: What Life Sciences Industry Wants

    What Life Sciences Industry Wants Decrease time to commercialization Ensure regulatory compliance ®2015 ®2015 Veeva Systems – Company Confidential Veeva Systems veeva.com |

98. Slide 98: The Industry is Changing. Fast.

    The Industry is Changing. Fast. Real-time External Partners Global Compliance & Vendors Markets ®2015 Veeva Systems veeva.com |

99. Slide 99: Trapped by Legacy Applications

    Trapped by Legacy Applications Collaboration  Core Function Focus  Local/Departmental Long, Complex Implementations & Globalization Upgrades Regulatory  Significant Customization or Compliance Configuration  Costly to Support On Premise  Nearly Impossible to Upgrade Departmental Solutions ®2015

100. Slide 100: Legacy Solutions are Complicated

     Legacy Solutions are Complicated Production Environment Content Accelerators Development Enterprise Search Disaster Annotation Server QA Recovery Rendition Server Application Server Custom Application Documentum ECM Oracle Database Server Monitoring Server Virus Protection File Storage Server Operat

101. Slide 101: Legacy Solutions…

     Legacy Solutions… Proliferated Across the Enterprise Submissions Quality eTMF Promotional Materials Medical ®2015 Veeva Systems veeva.com |

102. Slide 102: Technology Landscape: Costly and Complex

     Technology Landscape: Costly and Complex Millions spent on maintenance Numerous vendors Countless software versions Multiple systems for the same function across geographies Multiple data centers ®2015 Veeva Systems veeva.com |

103. Slide 103: Business Impact: Slow and Inherently Risky

     Business Impact: Slow and Inherently Risky Greater Compliance Risk 21.3% Productivity Loss Extended Timelines More Time Wasted on: Searching Reporting $19,000 lost per worker Updating Preparing for Audits Increased Costs 213 excess employees! IDC Bridging the Information Worker Productivity Gap 09/1

104. Slide 104: A New Solution is Needed ....

     A New Solution is Needed …. The Answer Monolithic Repository Content Replication System Integration ®2015 Veeva Systems veeva.com |

105. Slide 105: Veeva Vault: Simplifying Technology, Streamlining Business

     Veeva Vault: Simplifying Technology, Streamlining Business Applications & Platform ®2015 Veeva Systems veeva.com |

106. Slide 106: What Makes Vault Unique

     What Makes Vault Unique World-class Deep Built-in Cloud Industry Regulatory Platform Apps Compliance ®2015 Veeva Systems – Company Confidential veeva.com | ®2015 Veeva Systems veeva.com |

107. Slide 107: Veeva Vault Enterprise Suite

     Veeva Vault Enterprise Suite Clinical Regulatory Commercial Collect Manage Submit Publish Track Sell Archive Market Quality Platform ®2015 Veeva Systems veeva.com |

108. Slide 108: A Single Source of the Truth

     A Single Source of the Truth Increase Internal & Decrease Cost External of Compliance Collaboration Single Single Global Authoritative Authoritative Source Source End-to-End Decrease Process Time to Visibility Market ®2015 Veeva Systems veeva.com |

109. Slide 109: Process Transparency

     Process Transparency ACROSS PARTNERS ACROSS ACROSS DEPARTMENTS REGIONS ®2015 Veeva Systems veeva.com |

110. Slide 110: Best of Both Worlds

     Best ofvs. Global Both Worlds Decentralized Traditional Act Local Traditional global decentralized Be Global Easier to maintain Meets local requirements Easy to maintain Lower cost to operate Speed at local level Low cost to operate Does not meet local Costly, no sharing requirements Fast to impleme

111. Slide 111: Veeva R&D Suite

     Veeva R&D Suite Vault Clinical Vault Regulatory Collect Manage Submit Publish Track Archive Vault Quality Vault Platform ®2015 Veeva Systems veeva.com |

112. Slide 112: Veeva Vault Clinical

     Veeva Vault Clinical Vault Clinical Investigator Portal eTMF Site Document Built-in Study Collaboration Collection Standards Analytics Faster Cost Inspection Remove study start-up Savings Ready Bottlenecks ®2015 Veeva Systems veeva.com |

113. Slide 113: Top Pharma Company: 100% standardized on Vault eTMF globally

     Top 10 Pharma Company 100% standardized on Vault eTMF globally • Four disparate • Implemented Vault • Reduced compliance Benefit Solution Problem systems with manual eTMF across all risk through paper processes business lines standardized global processes • No global standards or • Single global Vau

114. Slide 114: Veeva Vault Regulatory

     Veeva Vault Regulatory Vault Regulatory Submissions Publish Archive Registrations Built in Complete Track & Manage Standards Traceability Registrations Faster Integration Decrease Improve Submissions Ready Approval Local Assembly Times Compliance ®2015 Veeva Systems veeva.com |

115. Slide 115: Innovative Biotech: Vault Submissions implementation

     Innovative Biotech Vault Submissions implementation with migration from Documentum • Legacy • Implemented Vault • Addressed key findings Benefit Solution Problem Documentum/FirstDoc Submissions live with with standard workflows system 150 users • Reduced time to • Growing cost to • Successful migrat

116. Slide 116: Veeva Vault Quality

     Veeva Vault Quality Vault QualityDocs Standardize Control Train Track SOP Access & R&U Lifecycle Built-in Management Compliance Auditing Change Control Reduced Improved Globally Always Compliance Productivity & Enforced Best inspection- Risk Oversight Practices ready ®2015 Veeva Systems veeva.com |

117. Slide 117: EU Midsized BioPharma: Vault QualityDocs

     EU Midsized BioPharma Vault QualityDocs for globally distributed manufacturing documentation •Managing controlled quality •Implemented Vault •Decreased compliance risk Benefit Solution Problem documentation across four QualityDocs globally and with global content & global sites and two replaced two

118. Slide 118: Using the Entire Veeva R&D Suite

     Using the Entire Veeva R&D Suite Vault Clinical Vault Regulatory Collect Manage Submit Publish Track Archive Vault Quality Vault Platform ®2015 Veeva Systems veeva.com |

119. Slide 119: Top Pharma: Standardizing on Vault Across the Enterprise

     Top 20 Pharma Standardizing on Vault Across the Enterprise •Archaic paper, file share, •Implemented eTMF for •Reduced risk and increased Benefit Solution Problem and homegrown systems Clinical live with nearly 1400 productivity by using Vault caused significant business global active sites, 780 acro

120. Slide 120: Vault Demonstration

     Vault Demonstration ®2015 Veeva Systems veeva.com |

121. Slide 121: Vault Momentum Since IPO

     Vault Momentum Since IPO 7x 100x 8x Vaults Documents Doc Views ®2015 Veeva Systems veeva.com |

122. Slide 122: World Class Platform: Performance Improvements

     World Class Platform: Performance Improvements 3.5 3 Avg Time (Seconds) 2.5 2 Doc View Search 1.5 Library 1 0.5 0 V7 V8 V9 V10 V11 V12 ®2015 Veeva Systems veeva.com |

123. Slide 123: Vault Delivers Significant Benefits

     Vault Delivers Significant Benefits Faster Time to Market Lower Compliance Risk Lower Costs Improve Global Visibility and Control ®2015 Veeva Systems veeva.com |

124. Slide 124: Customer Fireside Chat

     Customer Fireside Chat Ed Gemo ‎ ice President and Chief Information Officer – V Halozyme Therapeutics ®2015 Veeva Systems veeva.com |

125. Slide 125: Building a $1B+ Growth Company

     Building a $1B+ Growth Company Scale Products Customers ®2015 Veeva Systems veeva.com | 125

126. Slide 126: Questions

     Questions ®2015 Veeva Systems veeva.com |

Veeva Systems — Investor Day (September 2015) on 6ix